Cara Therapeutics Past Earnings Performance
Past criteria checks 0/6
Cara Therapeutics's earnings have been declining at an average annual rate of -4%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 4.5% per year.
Key information
-4.0%
Earnings growth rate
5.2%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | 4.5% |
Return on equity | -207.6% |
Net Margin | -565.2% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Cara Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 21 | -119 | 29 | 0 |
30 Sep 23 | 21 | -117 | 29 | 0 |
30 Jun 23 | 27 | -112 | 29 | 0 |
31 Mar 23 | 43 | -84 | 29 | 0 |
31 Dec 22 | 42 | -85 | 31 | 0 |
30 Sep 22 | 39 | -89 | 36 | 0 |
30 Jun 22 | 49 | -66 | 35 | 0 |
31 Mar 22 | 26 | -93 | 34 | 0 |
31 Dec 21 | 23 | -88 | 31 | 0 |
30 Sep 21 | 134 | 24 | 25 | -6 |
30 Jun 21 | 123 | 8 | 25 | 0 |
31 Mar 21 | 129 | 14 | 24 | 0 |
31 Dec 20 | 135 | 8 | 23 | 0 |
30 Sep 20 | 28 | -99 | 20 | 6 |
30 Jun 20 | 24 | -115 | 19 | 0 |
31 Mar 20 | 24 | -113 | 18 | 0 |
31 Dec 19 | 20 | -106 | 18 | 0 |
30 Sep 19 | 21 | -98 | 18 | 0 |
30 Jun 19 | 20 | -85 | 17 | 0 |
31 Mar 19 | 18 | -79 | 16 | 0 |
31 Dec 18 | 13 | -74 | 15 | 0 |
30 Sep 18 | 8 | -68 | 14 | 0 |
30 Jun 18 | 3 | -61 | 14 | 0 |
31 Mar 18 | 0 | -53 | 13 | 0 |
31 Dec 17 | 1 | -58 | 12 | 0 |
30 Sep 17 | 1 | -66 | 11 | 0 |
30 Jun 17 | 1 | -65 | 9 | 0 |
31 Mar 17 | 1 | -69 | 9 | 0 |
31 Dec 16 | 0 | -57 | 9 | 0 |
30 Sep 16 | 0 | -45 | 9 | 0 |
30 Jun 16 | 3 | -38 | 9 | 0 |
31 Mar 16 | 3 | -31 | 8 | 0 |
31 Dec 15 | 4 | -25 | 8 | 0 |
30 Sep 15 | 5 | -19 | 7 | 0 |
30 Jun 15 | 3 | -21 | 7 | 0 |
31 Mar 15 | 3 | -19 | 7 | 0 |
31 Dec 14 | 3 | -18 | 6 | 0 |
30 Sep 14 | 3 | -16 | 5 | 1 |
30 Jun 14 | 3 | -14 | 5 | 2 |
31 Mar 14 | 12 | -6 | 4 | 3 |
31 Dec 13 | 12 | -3 | 4 | 0 |
30 Sep 13 | 11 | -3 | 3 | 3 |
30 Jun 13 | 11 | 1 | 3 | 4 |
Quality Earnings: 69C is currently unprofitable.
Growing Profit Margin: 69C is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 69C is unprofitable, and losses have increased over the past 5 years at a rate of 4% per year.
Accelerating Growth: Unable to compare 69C's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 69C is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: 69C has a negative Return on Equity (-207.61%), as it is currently unprofitable.